MiMedx Group (MDXG) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed MiMedx Group (MDXG) over the past year, gaining 223.1% versus a loss of 34.9%. MiMedx Group is the larger company by market cap ($674.2 million vs $657.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | NVCT |
|---|---|---|
| Share price | $4.62 | $20.13 |
| Market cap | $674.22M | $657.12M |
| 1-day change | +0.22% | -0.79% |
| YTD return | -31.76% | +166.62% |
| 1-year return | -34.93% | +223.11% |
| 5-year return | -31.66% | — |
| P/E ratio (TTM) | 115.50 | — |
| Forward P/E | 23.10 | — |
| EPS (TTM) | $0.04 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $29.28 |
| 52-week low | $3.03 | $5.55 |
| Distance from 52-week high | -42.03% | -31.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +60.17% | +75.86% |
| Average volume | 1.23M | 217.91K |
| Shares outstanding | 145.93M | 32.64M |
| Employees | 808 | 16 |
| Sector | Health Care | Healthcare |
| Industry | Medical/Dental Instruments | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed MDXG by 258.0 percentage points over the past year.
- The two companies sit in different sectors: MiMedx Group in Health Care and Nuvectis Pharma in Healthcare.
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
MDXG vs NVCT FAQ
Which is bigger, MiMedx Group or Nuvectis Pharma?
MiMedx Group (MDXG) is larger, with a market capitalization of $674.22M compared with $657.12M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, MDXG or NVCT?
NVCT returned +223.11% over the past 12 months, compared with -34.93% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are MiMedx Group and Nuvectis Pharma in the same industry?
No. MiMedx Group is in the Health Care sector, while Nuvectis Pharma is in Healthcare.